Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the safety and tolerability of cediranib in
combination with Cisplatin plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese patients
with previously untreated locally advanced or metastatic unresectable gastric cancer (GC).